Candice has a BS in Mass Communications from Emerson College. Prior to that, Tom held an Operations Supervisor role at Bracebridge Capital, LLC and operations positions at Harvard Management Company and State Street Corporation. All information is subject to change and may quickly become unreliable for various reasons, including changes in market conditions or economic circumstances. He researched HIV at Harvard, where he earned his PhD, and then co-founded RA Capital Management, a Boston-based life-sciences investment firm focused on funding and creating companies developing new medicines. Angela Pontius is Vice President of Clinical Operations at RA Ventures (RAVen). Adam has 20+ years of industry experience in building healthcare and technology companies, including as CEO and co-founder of Link Medicine, a company focused on developing disease-modifying neurodegenerative therapies and as CEO and co-founder of Teleos Therapeutics, an innovative neuroscience drug discovery platform company. Prior to joining RA, Nadim was at NYU School of Medicine as Associate Dean of Therapeutics Alliances, a drug discovery accelerator that de-risks academic research towards partnerships with biopharma, investors, and nonprofits. Kyle's primary responsibility at RA is to lead investments in private companies that are developing innovative solutions to address climate change and environmental sustainability. He is also the co-founder of multiple biotechnology companies including HiFiBiO and Design Pharmaceuticals. Vikram Sheel Kumar is a Venture Partner at RA Capital where he is applying software to develop drugs and new ventures. Jacqueline has a BS with a double major in Molecular and Cellular Biology & Earth and Planetary Sciences from Johns Hopkins University. Christy has an MS in Immunology from National Taiwan University, a PhD in Immunology and Microbial Pathogenesis from Cornell University, and a mini-MBA in BioPharma Innovation from Rutgers Business School. Max DeNies is a Senior Associate with the TechAtlas division of RA Capital Management. Ed began his career working with neurologically active compounds at Allergan, CoCensys, and Serono. Tyler Kowalski is an InteractiveDesigner at RA Capital Management. Peter Kolchinsky, RA Capital's founder and managing partner. in Biochemistry and a Ph.D. in Pharmaceutical Sciences from the University of Toronto, Canada. He served on the Board of Global Science and Technology for the National Academy of Sciences, is the author of The Entrepreneurs Guide to a Biotech Startup, and frequently writes and speaks on the future of biotechnology innovation. Prior to joining RA, Brigid was the Head of Venture Investments for BHP Ventures, the internal venture capital unit within the worlds largest mining company, where her investment mandate was to help the decarbonization of BHPs operations and to improve the sustainability of resource extraction. Her primary responsibilities are to support our Venture Team by coordinating management agendas, calendars, and external events. At BPS, Joe provided technical support for teachers and staff and was Jamf certified to manage Apple products. He holds a BA in History from University of Massachusetts, Amherst and a Master's of Urban Affairs from Boston University. Rez brings to RA over 20 years of experience working in the life-science industry. Rebecca Silberman is an Analyst on the Venture Team at RA Capital Management. Candice previously worked as the Director of Executive Office and Administration at Flywire. No Patient Left Behind | Steering committee | Peter Kolchinsky Matthew works on both public and private investments and serves as a Board Director for Cerebral Therapeutics, DTx Pharma, Emergence Therapeutics, Forge Biologics, Jnana Therapeutics, and Kira Pharmaceuticals. He holds additional board appointments with several well-respected nonprofit organizations, including the Institute for Clinical and Economic Review (ICER), the Personalized Medicine Coalition, the Harvard Business School Healthcare Initiative, NEHI (Network for Excellence in Health Innovation), and the Massachusetts Rare Disease Advisory Council. Tess works on both public and private investments and serves on several company boards. Daniels primary responsibility at RA Capital is to edit and guide development of competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Peter served on the Board of Global Science and Technology for the National Academy of Sciences and writes about the biotech social contract. Eric holds a MAcc from Bentley University and a BS in Finance from George Mason University. Mariagrace has a BS in Sociology from Suffolk University. Emilies primary responsibility at RA Capital is to manage current and potential investor relationships. Andrew Levin is a Partner and Managing Director on the Investment Team at RA Capital Management and spearheads a drug discovery effort that has led to the formation of several new companies. Sophie is Chief Medical Officer at Enara Bio, a company focused on novel targets for cancer immune therapy drug discovery. Her doctoral research focused on bacteriophage-mediated regulation of bacterial transcription. Benjamin Hicks is a Venture Operations Associate at RA Capital Management. Craig holds a BA in Political Science from Bridgewater State College and a JD from Boston College Law School. Jaimie Kirkpatrick is a Research Assistant at RA Capital Management. Josh was previously co-lead of SV Health Investors US Biotech practice where he was responsible for SVs US venture creation activities, including its incubator, Brahma Discovery. Prior to RAVen, Scott was President and Managing Director of The Branta Group LLC, a healthcare company formation, capital investment, and strategic advisory firm known for taking an active management role with its clients and portfolio companies in the biotechnology, medical device, diagnostics, venture capital, and private equity sectors. Her primary responsibilities are to assist with all finance operations related to the Firm. Emily holds a BS in Graphic Design from James Madison University. Michael earned a DVM at the University of Pretoria and a PhD in Immunology at the University of Pennsylvania. Christina holds a PhD in Neuroscience from the Ichan School of Medicine at Mount Sinai and a BS in Biochemistry from Stockholm University. Prior to co-founding Therapeutics Alliances, Nadim worked in NYUs Industrial Liaison technology transfer group, and was a Research Analyst at the International AIDS Vaccine Initiative. Previously, Derek covered solid tumor oncology landscapes. Abhishek's primary responsibility is to identify needs for process improvement in the firm's data analytics and then both build and implement automated solutions. Previously, was a Research Analyst in the Kauwe lab at Brigham Young University. He is a respected biotech leader with over twenty years of biopharma experience across global organizations. Megan Lipcsey is an Associate with the TechAtlas division of RA Capital Management. Prior to Indigo, Kathryn was Investment Principal at the Massachusetts Clean Energy Center (MassCEC) where she invested in enterprise and consumer-facing clean energy companies, including software and hardware companies focused on utility and grid resilience, grid edge, next-generation renewables, efficient mobility, industrial efficiency, sustainable buildings, and the water-energy nexus. Jon has a PhD in Biomedical Engineering from the University of Michigan, an MS in Mechanical Engineering from Boston University, and a BS in Physics from the University of Washington. Michaels primary responsibility is to conduct research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. RA Capital | Team Peter Kolchinsky graduated from Harvard with a Ph.D. in virology in 2001. Before SV, Josh was President and Managing Partner at MRL Ventures Fund, the early-stage therapeutics-focused corporate venture fund within Merck & Co. Eric previously served as Director, Chief Risk and Compliance Officer, Americas at Aberdeen Asset Management. Prior to her Managing Director role at NVF, Nandita held various positions at Novartis in Business Development and Licensing and as a key member of the Kymriah Global Program Team, helping to bring this novel cell therapy to market. This ground-breaking new book, The Great American Drug Deal: A New Prescription for Innovative and Affordable Medicines (January 20, 2020), by Peter Kolchinsky, PhD, examines the healthcare landscape through the lens of the biotech social contract with America - the implicit agreement between the biopharmaceutical industry and American society - including the government's role in inventing . RA Capital makes no guarantees as to their accuracy or completeness. Peter Kolchinsky Net Worth (2023) | wallmine Tim began his career at Merck & Co., serving in multiple commercial roles in its cardiovascular, gastrointestinal, and managed care divisions. Joes primary responsibility at RA is to provide technical assistance and support for issues related to computer systems, the network, and server environments. In this role, he will work to evaluate and incubate early-stage therapeutic programs. After joining RA Ventures as Chief Development Officer, Ed built the development team, oversaw development of six compounds from discovery-stage through to clinical-stage, and led the formation of several new companies, including Lusaris Therapeutics. Jon Lundt is a Senior Associate within the TechAtlas division of RA Capital Management. Alex Martinez-Forte is an Analyst, Strategic Finance at RA Capital Management. He held senior management positions at two successful start-up companies that were acquired and he has over 14 years of experience investing in the global healthcare sector, both as a Partner and Managing Director at Matrix Capital Management and as a General Partner and Managing Director at Ayer Capital Management, a healthcare-focused hedge fund. Prior to MPM, she worked as an Executive Assistant at Charles River Ventures. Pieters primary responsibility at RA Capital is to lead major strategic initiatives and drive operational excellence across the firm. He holds BA and MA degrees in immunology from the University of Cambridge, an MD from University College London, and an MAS in clinical research from UCSF. Scott received his Bachelor of Science from the University of Illinois and his Ph.D. from the Massachusetts Institute of Technology. Fuad has a BA in Biology with a Minor in Psychology and earned a PhD in Biological Chemistry, both from Washington University in St. Louis. Kat Riesen is the VP, Finance at RA Ventures (RAVen). He holds a BA in Neuroscience with a minor in Molecular and Cellular Biology from Colorado College. Medicare 'negotiating' drug prices will hurt Americans, not help - STAT Prior to Q32 Bio, Maryann worked as the Operations Manager for Surface Oncology and several other biotech start-up companies from discovery research through end of Phase 2 Clinical trials. She previously held roles as a Senior Business Analyst at Cambridge Associates and a Systems Analyst at Wellington Management Company. Joel received his doctorate in Organic Chemistry from Columbia University and his bachelors in Chemistry from the University of Pennsylvania. Josh Resnick is a Senior Managing Director at RA Capital Management. Sarah earned her BA from Harvard College in East Asian Studies and her JD from Harvard Law School. The market worked. Pieter previously worked as a consultant with McKinsey & Company, where he managed a variety of healthcare engagements, including pharmaceutical mergers, biotech product launch plans, OTC product rationalization, and hospital acquisitions. Peter Kolchinsky | RA Capital Management Profile - TipRanks.com Prior to CVS Health, Prithviraj was a Senior Research Associate at the Gerson Lehrman Group. Adam has led and advised companies in diverse areas such as digital health, materials and diagnostics, and has served as Director on the board of multiple venture-backed companies. Prior to Schrdinger, Cony was President Chief Business Officer at Proteros responsible for all commercial activities. Dan Guglielmo is IT Operations Associate at RA Capital Management. Emily Gransky is VP of Recruiting at RA Ventures (RAVen). He was also responsible for initiating the transition of the autoimmunity strategy from one based on systemic immunosuppression to a targeted immunomodulation approach. Lucas Guevara is a Compliance Counsel at RA Capital Management. Garrett has over 20 years of experience in cell and gene therapy, including over 12 years in roles of increasing responsibility in biotech companies, including with Bluebird Bio, Audentes Therapeutics, and Ambys Medicines, and he was most recently the VP of Gene Therapy at Voyager Therapeutics. David Migl is an Analyst on the Investment Team at RA Capital Management. David is Director of Treasury at RA Capital Management. Milind has co-authored more than 80 scientific articles, is co-inventor on 30 patents, and is a frequent speaker at international scientific conferences. Gabe has a BS in Biology from Cornell University and a PhD in Biology from Northeastern University. Neil has spent five years at RA Ventures where he was most recently Vice President, CMC and worked across new company formation and in support of portfolio companies. Prior to RAVen, Cosmas was an Entrepreneur in Residence at Third Rock Ventures and was part of the teams that built Asher Bio (cell targeted biologics for oncology/autoimmune diseases) and Septerna (GPCR focused drug discovery) as well as other NewCOs in development. He completed the Executive Program at Stanford University, Graduate School of Business, as well as the Executive to Leader Institute at Korn/Ferry International. Joe brings to RA fifteen years of IT experience, beginning at the Apple Store and then transitioning to Boston Public Schools as an Apple Support Specialist. Elena's primary responsibility at RA Capital is to create competitive landscapes of biotechnology and planetary health. Josh holds a BA in Chemistry from Williams College, an MD from the University of Pennsylvania School of Medicine, and an MBA from the Wharton School of Business. Ally Boertzel is an Executive Assistant at RA Ventures (RAVen). Prior to founding The Branta Group LLC in 2003, he was a co-founder and Chief Business Officer of Orchid GeneShield, a subsidiary of Orchid BioSciences (Nasdaq: ORCH), which was formed after he acquired a healthcare informatics company and merged it with Orchids pharmacogenetics business to create innovative personalized consumer healthcare products in partnership with leading healthcare companies. Matt Beverly is a Senior Software Engineer at RA Capital Management. January 3, 2023 Feb 10th, Ed. She also gained administrative and client services experience in roles she held at Life Time Athletic, EF Education First, and at Beth Israel Deaconess Hospital ICU. Michael is Executive Vice President at Capstan Therapeutics. Her primary responsibilities are to support our Venture Team by coordinating management agendas, calendars, and external events. James has over 25 years of industry experience in creating and building biotechnology companies including experience as a co-founder of the lysosomal storage diseases company Vtesse acquired by Sucampo/Malinkrodt, co-founder of the clinical stage neuroendocrine company Tiburio, Board Director of the ocular gene therapy company Nightstar acquired by Biogen, and as founding Chief Scientific Officer of the rheumatology therapy company Synovex/Adheron acquired by Roche. Peter Kolchinsky Age : 46 Linked companies : ARS Pharmaceuticals, Inc. - Research Alliance Corp. II - Wave Life Sciences Ltd. - Icosavax, Inc. Summary Peter Kolchinsky is a founder and Managing Partner at RA Capital Management and author of The Great American Drug Deal. Ramin Farzaneh-Far is a Venture Partner at RA Capital where he works closely with RAs Venture Team to evaluate drug discovery platforms and initiate novel therapeutics programs. Sarah began her legal career with Foley, Hoag, & Eliot LLP. Michael Gillespie is an Analyst on the Venture Team at RA Capital Management. Peter Kolchinsky is a founder and Managing Partner at RA Capital Management and author of The Great American Drug Deal. She also has a Master's in Accounting from Boston College and is a CPA. While at BMS, Joel and his colleagues made notable advances in the area of kinase inhibitor drug discovery, particularly in immunology and oncology. Sonia Kartha is an Associate with the TechAtlas division of RA Capital Management. EMEA +44 20 7330 7500. She earned an MBA with focus in entrepreneurship & strategic management from AB Freeman School of Business at Tulane University and her MD from Tulane School of Medicine. As Head of Vaccines, he is leading the RA vaccine team to support our evidence-based investment strategy. Phi previously worked as an Executive Assistant at Relay Therapeutics. Prior to joining RA Capital, Alonso was Chief Technology and Innovation Officer at Ra Pharmaceuticals until it was acquired by UCB in 2020. Peter Kolchinsky Ding Sun is a Senior Software Engineer at RA Capital Management. Prior to this, he was a Postdoctoral Fellow at NYU Medical School in the laboratory of Dr. Danny Reinberg, exploring the functional downstream consequences of changes to the histone posttranslational modification landscape on processes that require access to DNA, including the regulation of gene expression. Soumya spent time as an EIR at IncTank Ventures, where he worked on multiple company creations. Peter Kolchinsky is a father, scientist, investor, teacher, and author. Ben previously worked as a Research Assistant in a Neuroinflammation lab at Brigham and Womens Hospital/Harvard Medical School, and was an Internet Application Developer at the Gallup Organization. Chris primary responsibility at RA Capital is to oversee the firms information technology program, including operations, development, and security. At Corning, he held a number of sales and marketing roles with increasing responsibility; in his last position at Corning, Cony was responsible for marketing at a new business unit focused on high-throughput screening and molecular biology products. He also supports select RAVen portfolio companies in active strategic operating roles and serves as Board Director for GIVax, Summation Bio, and Astro Therapeutics. His primary responsibilities are to assist with accounting, financial reporting and investment valuation. She is on the Steering Committee for No Patient Left Behind, a non-profit focused on reforming American healthcare to make medicines affordable to patients and promote innovation. In these commercial roles, he initiated innovative discovery deal structures with venture companies, research foundations, and large integrated deals with pharmaceutical companies. Rezs primary responsibility is to lead early-stage private investments in, and oversee the creation of, new companies developing therapeutics and other medical technologies. Benjamins primary responsibilities at RA Capital are to coordinate various projects across the Venture Team and oversee their initiation, planning, and execution. James was an entrepreneur in residence at HealthCare Ventures, an advisor to Kurma Ventures, and is on the Scientific Advisory Board and Board of Directors of the Friedreichs Ataxia Research Alliance (FARA), a patient advocacy group. Prior to RA, Megan worked as a Gastroenterology Fellow at University of Pittsburgh Medical Center and a Resident Physician, Internal Medicine, at Beth Israel Deaconess Medical Center. Prior to MP, she was a Consultant at Clarion Healthcare. Prior to Avilar, Mr. Grau was CEO at Sojournix, President at Heptares Therapeutics (acquired 2015), CEO at Cortria (acquired 2010), and COO at CombinatoRx (IPO 2005). Maryann Vigliotta is the Vice President of Operations and HR at RA Ventures (RAVen). Most recently, she was as an Entrepreneur-in-Residence at RA Ventures and was a Scientific Co-Founder and Associate Director of Corporate Development at Athenen Therapeutics (merged into Eliem Therapeutics; ELYM). In this role he works closely with the RA Ventures team to evaluate and incubate early stage therapeutic programs. Le Ho is a Business Systems Analyst at RA Capital Management. Prior to PwC, Brendan worked as Senior Tax Analyst for Highfields Capital Management LP and held tax and accounting positions at Citi and Investors Bank & Trust / State Street. Ross has a BS in Biochemistry from University of Oregon and a PhD in Pharmacology & Molecular Sciences from Johns Hopkins University. Timothy Noyes is an Advisor for RA Capital Management. Peterconducts due diligence on biotechnology companies at RA Capital, and advises RA's portfolio companies on many aspects of program and pipeline strategy. Angela's primary responsibilities at RAVen are to lead development and oversee implementation of best practices in clinical strategies in RA's newcos and portfolio companies. Tylers primary responsibility at RA Capital isdesigning and maintaining the RA Capital website and assisting in the creation and design of interactive platforms at RA Capital and it's portfolio companies founded through the firm's incubator, RA Ventures. Daniels primary responsibilities include creating competitive landscapes of climate change solutions and analyzing investment opportunities across climate technology and applied biotech. Prior to KPMG, TJ worked within the AP/Office Admin function with the Boston Red Sox. Mariagrace previously worked as an Executive Assistant at MPM Capital. Lucas holds a BA in Criminal Justice and Philosophy from John Jay College of Criminal Justice in NY, a JD, Privacy Concentration, from Northeastern University School of Law, and is admitted to practice law in MA. Kate McKenna is a Compliance Associate at RA Capital Management. He has over 20 academic publications, inventorship on numerous patents, and serves as reviewer for multiple journals and NIH grants committee. So it's not patents holding back production. He was Chief Medical Officer of Ra Pharmaceuticals from 2016 until it was acquired by UCB in 2020. Assistant General Counsel (RA Capital), RAVen Counsel. in Life Science from National Taiwan University, M.S. Vanderpump Rules: How Old Is Peter Madrigal? - Screen Rant Peter Kolchinsky on Twitter Joels first role in Biotech was as Chief Scientific Officer at Achillion Pharmaceuticals, where he led discovery efforts on Factor D inhibitors for the treatment of Paroxysmal Nocturnal Hemoglobinuria and C3 Glomerulopathy. Danielle Feldman is the Director of Corporate Development at Aliada Therapeutics. Robert has led multiple DARPA, IARPA, and NIH advanced technology development programs. Laura previously worked at WinterWyman where she served as a Senior Associate. Alex has a BA with a triple-major in Finance, Economics, and Math from UMass Lowell. Support. Tom Thomas is an Associate with the TechAtlas division of RA Capital Management. Ryan has a BS in Business Administration with a concentration in Accounting and Sports Management from Isenberg School of Management at University of Massachusetts, Amherst. Henry has a BA in Biology & Economics from Dartmouth College. TJ is a Senior Fund Accountant at RA Capital Management. Tweet With huge thanks to RA Capital's Alex Martinez-Forte and Jacqueline Rhuda for extensive data analysis. She is a CPA. Dings primary responsibility at RA Capital is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. In this role, Emily works closely with senior leaders, Venture Partners and Managing Directors within the Venture Team at RA Capital and within RAVen. Kates primary responsibilities are to drive internal and external strategic and diligence initiatives and oversee the workflow and professional development of TechAtlas Associates. James McArthur is an Advisor for RA Capital Management. Prior to RAVen, he was a member of the founding team and Chief Operating Officer at Catamaran Bio, a CAR-NK cell therapy company. Angela previously held roles as Senior Director of Clinical Operations and Patient Advocacy at Vigil Neuroscience and at Ra Pharmaceuticals. Prior to joining RAVen, Michael was the Executive Vice President and CMO at Point32Health, formed by the merger of Harvard Pilgrim Health Care and Tufts Health Plan. Monica Stanciu is an Associate Director within the TechAtlas division at RA Capital Management. Prior to external consulting and engineering, he gained experience in Helpdesk Specialist and Systems Administrator roles at Withum and Edelstein and Company, LLP. Nandita Shangari is joining RA Capital from Novartis Venture Fund (NVF), a life science investment firm, where she was a Managing Director. Tim received his A.B. Emily started her career in strategy consulting at Frankel Group. Garrett has worked cross-functionally across the landscape of in vivo and ex vivo genetic medicine modalities, often at the interface of payload design, platform research and manufacturing, IND-enabling activities, bioanalytical and computational biology, and strategy. Dan studied Network Communications & Information Services at Lincoln Technical. Brian is a IT Operations Manager at RA Capital Management. GREENWICH Peter Crumbine, a mainstay of public service in Greenwich for decades whose level-headed, friendly and professional manner earned . Robert received his BS in mechanical engineering from the University of Houston. Peter Kolchinsky - RA Capital Management - Insider Monkey He was a faculty member at the University of Rochester School of Medicine prior to joining Merck Research Laboratories in 2004. Adam was most recently President, CEO and member of the Board of Directors of Rodin Therapeutics until its acquisition by Alkermes in 2019. In this role he works closely with RAs Venture Team to evaluate various drug discovery platforms and initiate novel therapeutics programs. His graduate research investigated innate immune responses after intracerebral hemorrhage. Peyman Hosseinchi is an Associate within the TechAtlas division of RA Capital Management. Any views expressed were prepared based upon information available and believed to be reliable at the time such views were written. Tom holds a BS in Health Sciences with a minor in Journalism from Northeastern University. In this episode Peter speaks with Dr. Wayne Shreffler, Director of the Food Allergy Center at Massachusetts General Hospital & Division Chief of Pediatric Allergy and Immunology at MassGeneral Hospital for Children. Prior to joining RA Capital, Emilie was a Vice President of Investor Relations at THL Credit. Daniel Grau, an experienced biotech entrepreneur and operating executive, currently serves as CEO and Director at Avilar Therapeutics, a leading extracellular protein degradation company. Angela also gained experience in prior roles as Clinical Trial Manager at Roche, Sarepta, and other companies, and Clinical Research Coordinator at Tufts Medical Center and Dana-Farber Cancer Institute. A trained cardiologist, he has held academic faculty positions at the University of California, San Francisco (UCSF) and the University of Texas Southwestern Medical Center. Cosmas brings to RAVen over a decade of leadership experiences at the interface of basic science, drug development and clinical care. Mr. Grau earned his BA with High Honors from Davidson College, where he was awarded a Dana Honor Scholarship and elected to Phi Beta Kappa, and his MPhil, MA, and MAR degrees from Yale University, where he was awarded the Day Graduate Prize and was the recipient of a Mellon Fellowship in the Humanities. He is the co-inventor of first-in-class HCV NS5A inhibitors, which led to the approval of DaklinzaTM, the first marketed drug in its class. Prior to this role, Erich mapped a number of competitive landscapes including lung cancer, obesity, and chronic kidney disease. He has more than 15 years of experience in investing, company formation, and company leadership across all stages of drug development, from discovery through commercialization. Toms primary responsibility is to support all aspects of trade and treasury operations. Joe DeMaio is IT Operations Associate at RA Capital Management. Soumya obtained his PhD in X-ray Crystallography and Biophysics from the Indian Institute of Science while working as visiting research scholar at Rockefeller University. Phi's primary responsibilities at RA Capital are to support the Operations team by coordinating calendars, events, and company meetings. His research investigated chromatin structure and transcription factor binding. Brett Scheller is a Compliance Officer at RA Capital Management. Samuel Chowdhury is a Software Engineerat RA Capital Management. Prior to RA, Chris was at Elsevier Business Intelligence, where he served as Writer/Editor and eventually became the Editor in Chief for Biopharmaceuticals and Consumer Products.